<img src="https://ml.globenewswire.com/Resource/Download/d6272c2e-d204-41b8-b545-a6e2e24f85c2?size=2" nborder="0" align="left" hspace="5" vspace="5" title="sns insider pvt ltd.png" alt="SNS Insider pvt ltd"/>The U.S. Peptide and Oligonucleotide CDMO Market is projected to reach USD 3.26 Billion by 2035, while Europe is expected to reach USD 2.93 Billion, supported by expanding biopharmaceutical outsourcing, peptide therapeutics, and precision medicine manufacturing.Austin, United States, July 24, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.globenewswire.com/Tracker?data=FWfP1VLNTub0VUGwX3YZQJJZQ1NbkhvFEy2Nz6SNIZCRvCcH2ZJc4T6D3CxeZgVDnHLq2Z79rLypY3A0jw0ub7GOx2FzmRtvCr7Cs-IsYslRl7g7eQ1qNx09CHOuSxg-8yT14o-DdPefiW9vS8boNVXrKC9sFBWwTfUh0_F_NEqenckn9ekp2xzcQ5tMEfLJu3vz9j15ce3AqUDJ9ClIzQ==" rel="nofollow" target="_blank" title="Peptide and Oligonucleotide CDMO Market">Peptide and Oligonucleotide CDMO Market</a> Size was valued at USD 3.34 Billion in 2025 and is projected to reach USD 11.42 Billion by 2035, expanding at a CAGR of 13.10% during 2026–2035, according to a new report by SNS Insider. Growing demand for peptide therapeutics, oligonucleotide-based medicines, biopharmaceutical outsourcing, and precision medicine manufacturing continues to accelerate global market growth. The market for Peptide and Oligonucleotide CDMO is expanding owing to the growing trend towards outsourcing of biopharmaceutical manufacturing, increasing need for peptide drug treatments, and issues surrounding efficient manufacturing of peptides for precision medicine and genetic therapies. CDMO firms offer manufacturing solutions using solid-phase and automated synthesis approaches to enhance the quality and scalability of the manufacturing process. <img alt="Peptide And Oligonucleotide CDMO Market" height="400" src="https://ml.globenewswire.com/Resource/Download/269adb6c-e8e2-4386-b3f5-1144ace8328c/peptide-and-oligonucleotide-cdmo-market.jpg" width="600" data-dpi="96" data-filename="Peptide-And-Oligonucleotide-CDMO-Market.jpg" /> Download the Peptide And Oligonucleotide CDMO Market Sample Report: <a href="https://www.globenewswire.com/Tracker?data=9j8lhuzRhAiX8pEIrys2H2Ob1noCZHbQmeAxoexGiS_dTLw1kFJXF_Nhct98f04UA7WriD79rpiOOSY5fn7OpjJyLJ2xldaRdUB4eg2dCJz_m-cv9BJpdLf0fpv4PqWQTxToCtypq_yxWs1XGglBx_rg2bY51aUw-3UZgF-ZBbw=" rel="nofollow" target="_blank" title="">https://www.snsinsider.com/sample-request/10505</a> Biopharmaceutical Outsourcing and Peptide Therapeutics Drive Peptide and Oligonucleotide CDMO Market Growth Peptide and Oligonucleotide CDMO services are gaining popularity worldwide owing to increased complexity in synthesizing products which necessitates unique manufacturing capabilities. The pharmaceutical companies are aiming at improving efficiency through contract development and manufacturing services outsourcing. In addition, increased pipeline of biologics, the growing popularity of gene therapy and precision medicine have been contributing toward the rising trend. Moreover, technological developments such as automation in synthesis, digital process analytics and modular manufacturing are enhancing product quality and consistency. Segmentation Analysis: By Type Peptides commanded the Peptide and Oligonucleotide CDMO market with a 58.40% market share in 2025 due to its higher adoption in therapeutic drug discovery, cancer therapy, and metabolic disease treatment with an advanced manufacturing process and excellent molecule stability. The oligonucleotides segment is witnessing the highest growth rate of 16.38% CAGR owing to growing demand for precision drugs and genetic disease treatment applications. By Application Pharmaceuticals was the key sector accounting for 71.60% market share of the Peptide and Oligonucleotide CDMO Market in 2025 on the back of growing demand for drugs based on peptides and oligonucleotides for treating diseases, backed up by increasing outsourcing of biological drug production. The Diagnostics sector is witnessing the highest growth rate with 17.05% CAGR on account of growing adoption of molecular and genetic testing methods. By Synthesis Route Solid-Phase Synthesis was leading the Peptide and Oligonucleotide CDMO market with 64.80% market share in 2025 owing to the efficiency, reliability, and purity of peptides and oligonucleotides sequences produced using this manufacturing technique. The Automated Synthesis segment is the fastest growing with a CAGR of 19.96% on account of increasing need for highly efficient and error-free manufacturing techniques that involve robotics and AI-driven solutions. By Scale Clinical held the top position in the Peptide and Oligonucleotide CDMO Market, holding 46.85% market share in 2025, owing to the rising need for manufacturing late-stage drugs and clinical trial materials due to increased complexity resulting in dependency on CDMOs among the pharma and biotech organizations. The preclinical segment is witnessing the highest growth with a CAGR of 16.05%, owing to increasing drug discovery and toxicology tests. North America Leads the Peptide and Oligonucleotide CDMO Market While Asia Pacific Records the Highest CAGR North America Peptide and Oligonucleotide CDMO Market holds a share of around 38.60% in the global market in 2025 due to high outsourcing requirement and the presence of an advanced research and development infrastructure for biologic manufacturing. The increasing use of peptides in therapy, growth of the pipeline of precision medicine, and regulatory guidelines and standards further aid the growth of the regional market. The U.S. Peptide and Oligonucleotide CDMO Market was valued at USD 1.11 Billion in 2025 and is projected to reach USD 3.26 Billion by 2035, growing at a CAGR of 11.34%. Factors such as increase in outsourcing of peptides therapeutics manufacturing, increase in oligonucleotides drug pipeline and rising investments in precision medicine will lead to increased demand of CDMO services in the United States. The Europe Peptide and Oligonucleotide CDMO Market is estimated at USD 0.93 Billion in 2025 and is projected to reach USD 2.93 Billion by 2035, growing at a CAGR of 12.18%. Growth in the pharmaceutical manufacturing, biologics manufacturing and continuing investment in research on peptides and oligonucleotides will help market growth in Germany, France, UK and Switzerland. Asia-Pacific is the most rapidly growing geographical segment of Peptide and Oligonucleotide CDMO Market with a CAGR of about 15.52% from 2026-2035 due to growth in biotechnology manufacturing, increase in outsourcing of biologics, increase in pharmaceutical R&amp;D investment and competitive CDMO infrastructure in China, India, Japan, and South Korea. Explore the Complete Peptide And Oligonucleotide CDMO Market Report: <a href="https://www.globenewswire.com/Tracker?data=9j8lhuzRhAiX8pEIrys2H2Ob1noCZHbQmeAxoexGiS8UDSWhMunZpxZHPUwLuhqgtJxYLFx0cQrlK1hMXyn75TkE2nAB0ekLviG3uJMCd-qAJ41XXWI887Ij1iwsSIpcIXOSmDbazxN5DdueVk3Nql-0vF4gbW3xgR36nOmO_4P2VEmcPLLWvTdRbKVawiI8Df1MWZH7nPZma9pklxL6X76FVV6J8iaxSb_6gaUfYSWCGFzOIFZpXHmB_u-11VWN" rel="nofollow" target="_blank" title="">https://www.snsinsider.com/reports/peptide-and-oligonucleotide-cdmo-market-10505</a> Leading Market Players Listed in this Report are: <ul type="disc"><li style="margin-top:12pt; margin-bottom:8pt;">Lonza</li><li style="margin-top:12pt; margin-bottom:8pt;">Thermo Fisher Scientific</li><li style="margin-top:12pt; margin-bottom:8pt;">AGC Biologics</li><li style="margin-top:12pt; margin-bottom:8pt;">Samsung Biologics</li><li style="margin-top:12pt; margin-bottom:8pt;">WuXi AppTec</li><li style="margin-top:12pt; margin-bottom:8pt;">Bachem</li><li style="margin-top:12pt; margin-bottom:8pt;">PolyPeptide Group</li><li style="margin-top:12pt; margin-bottom:8pt;">CordenPharma</li><li style="margin-top:12pt; margin-bottom:8pt;">AmbioPharm</li><li style="margin-top:12pt; margin-bottom:8pt;">CPC Scientific</li><li style="margin-top:12pt; margin-bottom:8pt;">Almac Group</li><li style="margin-top:12pt; margin-bottom:8pt;">Evonik Industries</li><li style="margin-top:12pt; margin-bottom:8pt;">Siegfried Holding AG</li><li style="margin-top:12pt; margin-bottom:8pt;">Piramal Pharma Solutions</li><li style="margin-top:12pt; margin-bottom:8pt;">Pharmaron</li><li style="margin-top:12pt; margin-bottom:8pt;">Asymchem Laboratories</li><li style="margin-top:12pt; margin-bottom:8pt;">SK pharmteco</li><li style="margin-top:12pt; margin-bottom:8pt;">Porton Pharma Solutions</li><li style="margin-top:12pt; margin-bottom:8pt;">GenScript</li><li style="margin-top:12pt; margin-bottom:8pt;">Recipharm</li></ul> Recent Developments <ul type="disc"><li style="margin-top:12pt; margin-bottom:8pt;">2026: Thermo Fisher Scientific continues expanding pharma services and oligonucleotide manufacturing capabilities through global CDMO infrastructure investments and upgrades.</li><li style="margin-top:12pt; margin-bottom:8pt;">2025: Samsung Biologics expanded large scale biomanufacturing capacity with Plant 5 operations ramp and digital automation initiatives.</li></ul> Exclusive Sections of the Report (The USPs): <ul type="disc"><li style="margin-top:12pt; margin-bottom:8pt;">CDMO ADOPTION AND SYNTHESIS PERFORMANCE METRICS – helps you evaluate peptide and oligonucleotide CDMO adoption trends, service utilization, synthesis efficiency, and client retention indicators across major type categories and markets.</li><li style="margin-top:12pt; margin-bottom:8pt;">BIOPHARMACEUTICAL OUTSOURCING AND PIPELINE IMPACT METRICS – helps you understand the impact of biologics pipelines, gene therapy expansion, and precision medicine demand on CDMO outsourcing and evolving manufacturing strategies.</li><li style="margin-top:12pt; margin-bottom:8pt;">AUTOMATED SYNTHESIS AND OPERATIONAL EFFICIENCY METRICS – helps you identify how automation, digital process analytics, and modular facilities are improving production quality, scalability, and consistency capabilities.</li><li style="margin-top:12pt; margin-bottom:8pt;">CDMO TECHNOLOGY INNOVATION AND ADOPTION TRENDS – helps you assess the growth of solid-phase, automated, and scalable synthesis solutions designed to address changing pharmaceutical needs and manufacturing risks.</li><li style="margin-top:12pt; margin-bottom:8pt;">PRECISION MEDICINE AND GENE THERAPY INTEGRATION – helps you understand how CDMO services are supporting personalized treatment through the integration of custom manufacturing and small batch models.</li><li style="margin-top:12pt; margin-bottom:8pt;">REGIONAL MARKET AND COMPETITIVE LANDSCAPE ANALYSIS – helps you evaluate key markets, CDMO providers, government-supported programmes, market penetration, and strategic developments shaping the global peptide and oligonucleotide CDMO industry.</li></ul> Buy the Peptide And Oligonucleotide CDMO Market Report with Competitive Analysis and 2035 Forecast: <a href="https://www.globenewswire.com/Tracker?data=9j8lhuzRhAiX8pEIrys2H2Ob1noCZHbQmeAxoexGiS_KvI7yWG_gWY7EgSpYowi5s0Xj6SjFhOn4GUZy_lO3vgLsjHL8moIwBi-eicUs7KEXTbQtrFca3WJBiJqmH6WdECUbOssqlEMpu1K-MQjt5w==" rel="nofollow" target="_blank" title="">https://www.snsinsider.com/checkout/10505</a> Peptide And Oligonucleotide CDMO Market Report Scope <table align="center" style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Report Attributes</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Details</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size in 2025</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">USD 3.34 Billion</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size by 2035</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">USD 11.42 Billion</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">CAGR</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">CAGR of 13.10% From 2026 to 2035</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Base Year</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">2025</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Forecast Period</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">2026-2035</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Historical Data</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">2022-2024</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Key Segments</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">By Type (Peptides, Oligonucleotides, Conjugates) By Application (Pharmaceuticals, Diagnostics, Cosmetics) By Synthesis Route (Solid-phase Synthesis, Solution-phase Synthesis, Automated Synthesis) By Scale (Preclinical, Clinical, Commercial)</td></tr><tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regional Analysis/Coverage</td><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East &amp; Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East &amp; Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).</td></tr></table> Related Market Reports <a href="https://www.globenewswire.com/Tracker?data=FWfP1VLNTub0VUGwX3YZQAktXiFD4OwGhCWirZ-Lp_KXIh94dzQoOVZWV3NzM3SHRKIw9r40m5YIpjmVY0SaJx9GNz4umqkgu55MmDqV6NOR6IKx3nvuC8DHG57YM6LlAaJtznJcRhDfoHfsET7nD1iGZP83qOpJZqfkXIMgP5c=" rel="nofollow" target="_blank" title="Peptide Synthesis Market Size 2026">Peptide Synthesis Market Size 2026</a> <a href="https://www.globenewswire.com/Tracker?data=hPUfBXuXdTrwW3cUPXwi5-C6ZHJKdM7oQsw5fRVpRzYRtOh5rtkFuFPuZOFRd_5FH0RPTlxWrcd6g1ahV8cEWIUlQytgZcK5ao6IYkFxcxnrQ8SKNjtNpAln_FDvp_KCiJC6eA9u2QJZi-U_cjPrK2NYMSDO3tFq0FB_m0OGbfzovVK2yaNMllDh077ztXjP" rel="nofollow" target="_blank" title="Oligonucleotide Synthesis Market Growth 2026">Oligonucleotide Synthesis Market Growth 2026</a> <a href="https://www.globenewswire.com/Tracker?data=-SohWj0yIEGjw-gilxqj9arMHFcp8hBEiKtHuQZpXjP6If694RfqQrcSZm2Jjs1B0PaqDtZlFk3Pf3wxhqc54QUqIuwIgA0iVGA5p1eUMi3le9-ZjEqneVDc2zzxKtNJlB13SpiIhhAkPm9SmQRgURYQf8HHZjoqQuLkDGv3pJTCt1bwq5xp6H9m18iLqJWJUaT7FyukvjHPboKD_gtPTFfcld0YoS1298k2veT5LBc=" rel="nofollow" target="_blank" title="Pharmaceutical Contract Manufacturing Market Outlook 2026">Pharmaceutical Contract Manufacturing Market Outlook 2026</a> <a href="https://www.globenewswire.com/Tracker?data=rBdCYa_Furn-j4bBtFWdNwdA1LSismRlgFjiHMWgrJ_vZ1wuLvSA8NgGw8irFWgz0rkRyqFA60U6WVyMH67WOFuWqzXZoBW59dbubWl0uv8k16FtaVNL5j0SEMdBdQY-FIzSv5LmG8-EyIJHGMNC1w==" rel="nofollow" target="_blank" title="CMO/CDMO Market Trends 2026">CMO/CDMO Market Trends 2026</a> <a href="https://www.globenewswire.com/Tracker?data=3HvmOVN0SejOgV8GuizlHPxDASvDSckHhYsH5s9s15nkL34Dopg7B14BsCpJBsLqPe_-kMOu67Z05c6hatVDGqmfZTVaYKaSGzRyo8neQiVWmlGn2qzua_yUD-bXi2nCIYo9jrS9nXoDf1OuLap7Qma_vBxLV5GGwfSW7VB2JXG126Vftgm63Cq_wlLao4B5" rel="nofollow" target="_blank" title="Biopharmaceutical CMO Market Share 2026">Biopharmaceutical CMO Market Share 2026</a> About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. <pre>CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com
</pre> <img alt="" src='https://ml.globenewswire.com/media/MmZjMjAyN2YtZTRiZS00ZTkwLWIyNzEtYTFiYmNmMzQyYzY5LTEyNjg4MTktMjAyNi0wNy0yNC1lbg==/tiny/SNS-Insider-pvt-ltd.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Peptide and Oligonucleotide CDMO Market Size to Reach USD 11.42 Billion by 2035 | SNS Insider

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn